12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
Exploring future hair loss treatments, including immunosuppressants for hair transplants and hair cloning, with a focus on leveraging research from other medical fields. Current treatments like finasteride and minoxidil are effective for most, but there's a call for more funding and innovation in the hair loss industry.
Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
A new study that found a single chemical could potentially be responsible for hair loss, and the potential to use this discovery to stimulate hair growth. The conversation also includes various treatments such as Minoxidil, Finasteride, RU58841, microneedling, DUT, and Botox for hair loss.
Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.
L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.
A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.
A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
Hair loss treatments, such as Dutasteride, Minoxidil, and Finasteride. Advice is given to give the medications time to work and to consider a Hair Transplant in order to fill any gaps caused by continuing hair loss.
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
User tried DIY Dutasteride Mesotherapy for hair loss due to unsatisfactory Finasteride results. Used mesotherapy injection gun and liquid dutasteride for better results and fewer side effects.
Hair loss discussion includes broccoli sprouts treatment, Fluridil 7%, and sulforaphane, with mixed results. Finasteride, minoxidil, and RU58841 are preferred by some users.